GGrantIndex
← Leaderboards

Andreas Vogt

University Of Pittsburgh At Pittsburgh

$5,634,005
Attributed
$10,694,032
Total exposure
8
Grants
3
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.1M · FY200525
$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$10,694,032 · 8

By mechanism

R01$8,092,636 · 4
P01$1,092,397 · 1
R33$782,500 · 1
R21$726,499 · 2

Most similar at University Of Pittsburgh At Pittsburgh

Same institution · by research overlap

Others in their field

Top investigators on “Libraries

Research focus

LibrariesSmall MoleculeImageMouse ModelDoseResponseIn VivoGeneticCollectionLeadCellsMethodologyUnited States National Institutes Of HealthSmall Molecule LibrariesStructure-Activity RelationshipIn VitroProteinsCombinatorial ChemistryMediatingPathway InteractionsHigh Throughput ScreeningMutantEfficacy TestingToxic Effect

Grant awards (28)

High-content screening for TPI Deficiency therapeutics$548,111
R01 · FY2025 · HD
Developing the first TPI Df therapeutics$524,864
R01 · FY2025 · HD
High-content screening for TPI Deficiency therapeutics$550,305
R01 · FY2024 · HD
Developing the first TPI Df therapeutics$526,383
R01 · FY2024 · HD
High-content screening for TPI Deficiency therapeutics$543,301
R01 · FY2023 · HD
Developing the first TPI Df therapeutics$538,538
R01 · FY2023 · HD
High-content screening for TPI Deficiency therapeutics$589,328
R01 · FY2022 · HD
Developing the first TPI Df therapeutics$543,231
R01 · FY2022 · HD
High-content screening for TPI Deficiency therapeutics$578,477
R01 · FY2021 · HD
Developing the first TPI Df therapeutics$543,529
R01 · FY2021 · HD
High-content screening for modulators of lamin B1 as a therapeutic target in autosomal dominant leukodystrophy$391,250
R33 · FY2020 · NS · contact PI
High-content screening for modulators of lamin B1 as a therapeutic target in autosomal dominant leukodystrophy$391,250
R33 · FY2019 · NS · contact PI
High content in vivo screening for acute kidney injury ameliorating drugs$352,125
R01 · FY2019 · DK
High-content screening for modulators of lamin B1 as a therapeutic target in autosomal dominant leukodystrophy$390,626
R21 · FY2018 · NS · contact PI
High content in vivo screening for acute kidney injury ameliorating drugs$351,001
R01 · FY2018 · DK
High content in vivo screening for acute kidney injury ameliorating drugs$348,188
R01 · FY2017 · DK
Small Molecule Screens to Identify Probes for Studies of Repair and Regeneration$316,354
R01 · FY2016 · HD
Small Molecule Screens to Identify Probes for Studies of Repair and Regeneration$311,560
R01 · FY2015 · HD
Small Molecule Screens to Identify Probes for Studies of Repair and Regeneration$310,603
R01 · FY2014 · HD
Small Molecule Screens to Identify Probes for Studies of Repair and Regeneration$300,300
R01 · FY2013 · HD
Small Molecule Screens to Identify Probes for Studies of Repair and Regeneration$316,438
R01 · FY2012 · HD
Transformative HTS cell migration assay for rapid screening of cancer therapeutic$186,696
R21 · FY2011 · CA
Transformative HTS cell migration assay for rapid screening of cancer therapeutic$149,177
R21 · FY2010 · CA
CORE--BIOINFORMATION AND CELL-BASED ASSAY$272,155
P01 · FY2009 · CA · contact PI
CORE--BIOINFORMATION AND CELL-BASED ASSAY$248,231
P01 · FY2008 · CA · contact PI
CORE--BIOINFORMATION AND CELL-BASED ASSAY$230,370
P01 · FY2007 · CA · contact PI
CORE--BIOINFORMATION AND CELL-BASED ASSAY$194,564
P01 · FY2006 · CA · contact PI
CORE--BIOINFORMATION AND CELL-BASED ASSAY$147,077
P01 · FY2005 · CA